New hope for hard-to-treat cancers? experimental combo enters phase 2 trial
Disease control
Not yet recruiting
This study tests a new drug (GV20-0251) combined with an immunotherapy (anti-PD-1) in people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. About 227 adults with various cancers, including lung, breast, and colorectal, will participa…
Phase: PHASE2 • Sponsor: GV20 Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC